CEO MESSAGE

Syntekabio begins its leap to become a leading player in the fourth biohealth industry.
Genome big data company Syntekabio has been striving to establish a precision medicine and AI new drug development system. As the emergence of the Illumina next-generation genome sequence enables the analysis of genome big data and group-level genome integration, biomarkers for customized drug genes for individual patients and AI new drug development platforms are becoming the centerpiece of the fourth biohealth industry.
Therefore, based on the AI new drug development platform DeepMatcher®, which combines new drug development technology and genome big data technology, Syntekabio intends to contribute to various disease sensitivity and early diagnosis, which have been difficult to interpret. In addition, we will focus on technology investment and development until diagnosis and treatment converge with AI new drugs in the future and mutually synergy occurs.
Through various research and development, Syntekabio will develop with the most advanced technologies, from disease diagnosis to AI new drug platform technology, aiming for individual health and ultimate well-being.

Syntekabio CEO. Jung Jong Sun Ph.D.